Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Non-cash Items (2023 - 2025)

Historic Non-cash Items for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $19.9 million.

  • Contineum Therapeutics' Non-cash Items fell 4910.16% to $19.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year decrease of 4910.16%. This contributed to the annual value of $2.1 million for FY2024, which is 8579.55% down from last year.
  • As of Q3 2025, Contineum Therapeutics' Non-cash Items stood at $19.9 million, which was down 4910.16% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Non-cash Items ranged from a high of $39.0 million in Q3 2024 and a low of $2.0 million during Q1 2024
  • For the 3-year period, Contineum Therapeutics' Non-cash Items averaged around $14.5 million, with its median value being $8.9 million (2023).
  • Over the last 5 years, Contineum Therapeutics' Non-cash Items had its largest YoY gain of 956.68% in 2025, and its largest YoY loss of 9120.12% in 2025.
  • Quarter analysis of 3 years shows Contineum Therapeutics' Non-cash Items stood at $14.9 million in 2023, then crashed by 85.8% to $2.1 million in 2024, then soared by 839.01% to $19.9 million in 2025.
  • Its Non-cash Items was $19.9 million in Q3 2025, compared to $2.9 million in Q2 2025 and $2.2 million in Q1 2025.